SecBot SecBot
SECBOTREPLAY Home › Report › NGEN

NGEN · NervGen Pharma announced that the FDA granted Breakthrough Therapy…

NervGen Pharma Corp. · PRESS-RELEASE filed Nov 12, 2026 at 07:15 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Nov 12, 2026 at 07:15 ET

NervGen Pharma announced that the FDA granted Breakthrough Therapy designation to NVG-291 for chronic traumatic cervical motor-incomplete spinal cord injury, based on Phase 1b/2a CONNECT SCI data showing functional hand use improvements. The designation may expedite development and regulatory review, but does not guarantee approval.

  • FDA granted Breakthrough Therapy designation for NVG-291 in chronic traumatic cervical motor-incomplete SCI
  • Designation based on safety and efficacy data from Phase 1b/2a CONNECT SCI study
  • Phase 3 RESTORE registrational study is enrolling, targeting ~150 participants in US and Canada
  • NVG-291 is a first-in-class neuroreparative peptide targeting the CSPG-PTPσ pathway

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access